ObvioHealth raises $3 million to facilitate mobile clinical trials
Date: 2018-03-25   Author: Paroma Bhattacharya  Category: #news

ObvioHealth, one of the notable “site-less” clinical trial companies of Singapore, recently announced raising $3 million in a Series A funding round. Reportedly, the financing will help the firm in supporting its operational team and present growth requirements. The funding round has been led by TSK I, a venture fund that chiefly focuses on life science and healthcare initiative financing.

As per reliable sources, ObvioHealth will be digitizing the entire process in order to comply with Food and Drug Administration (FDA) Good Clinical Practices. The company has also been focusing on facilitating cost efficient and faster clinical trials.

For the record, ObvioHealth’s proprietary software, ClaimIt, supports interventional and observational studies, allowing real-time interactions with subjects, as well as integration with smartphones and connected devices.

CEO of ObvioHealth, Bryan Silverman reportedly said that CliamIt has become a go-to platform for sponsors who value cost and time savings that online clinical trials through ClaimIt can offer. He went on to add that ClaimIt is generating significant traction through its digital platform in therapeutic areas as it facilitates expensive and complex studies within the traditional model.

The venture fund TKS I has been formed by the SPRIM Ventures, the VC arm of SPRIM and Tikehau Investment Management. SPRIM is a global innovation firm focused on healthcare while Tikehau Investment Management is an investment and asset management group which manages assets that surpass US$17 billion in value.

In a statement, Tikehau IM Chairman Bruno de Pampelonne reportedly said that technology is to be thanked for the disruption caused in clinical trial industry. He further added that the firm is excited to receive this opportunity to support the growth of ObvioHelath with the Series A financing round. He expressed belief that since ObvioHelath is led by a team of experienced professionals with a detailed vision, the firm would soon become one of the global leaders in mobile clinical trial.



About Author


Paroma Bhattacharya

Paroma Bhattacharya

Paroma currently works as a content developer for AlgosOnline. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched content in diverse fields. Apart from...

Read More

More from Paroma


Post Recommendents

Walmart and JD.com provide $500m funding to Chinese logistics company
Author: Pankaj Singh

Dada-JD Daojia, a Chinese online grocery delivery service has reportedly raised USD 500 million in a recent funding round led by U.S. retail giant Walmart and Chinese e-commerce company JD.com. Sources inform that the ...


3D Systems & GF Machining team up to develop factory of the future
Author: Saif Ali Bepari

South Carolina based 3D Systems has reportedly announced a partnership with GF Machining Solutions with the aim of redefining how manufacturers think about their manufacturing setup. Sources cite that the new manufactu...


ITV invests USD 1 billion with Hollywood giants to launch NewT
Author: Ojaswita Kutepatil

ITV, a commercial television channel of the United Kingdom has reportedly collaborated with major Hollywood studios including 21st Century Fox, Disney, and others. Two huge Wall Street banks and the billionaire Walton ...